Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol Diphosphate SCHEMBL9370 | 0.96 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL6231203 | 0.96 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL2496868 | 0.95 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL809597 | 0.95 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707841 | 0.90 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL7617243 | 0.90 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707840 | 0.90 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL14608595 | 0.87 | BLM (0.81) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL5488347 | 0.83 | BLM (0.74) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL8937910 | 0.82 | BLM (0.72) | BLMNR1I2SMN1; SMN2ESR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303494-B2 | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer | GLAX Health LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220235422-A1 | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER | GLAX Health LLC (US) | 2022-07-28 | — | — | US | disclosed |
| EP-2237792-A1 | ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHODS | Vaccinex, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009082485-A1 | ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHODS | VACCINEX, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| EP-1165785-A4 | 48 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1175503-A1 | 49 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1165785-A1 | 48 HUMAN SECRETED PROTEINS | Human Genome Sciences, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000066608-A1 | TUMOR NECROSIS FACTOR-GAMMA | HUMAN GENOME SCIENCES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000061779-A1 | 49 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000058469-A1 | 48 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303494-B2 | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer | NCOA2, ESR2, NUCB2 | ESR1 128/4885ESR2 2/4885BLM 3714/4885 |
| US-20220235422-A1 | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER | NCOA2, ESR2, NUCB2 | ESR1 128/4885ESR2 2/4885BLM 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.